-
1Academic Journal
Συγγραφείς: N. D. Kobzeva, V. P. Terentev, V. D. Oleinikova, Н. Д. Кобзева, В. П. Терентьев, В. Д. Олейникова
Πηγή: The Russian Archives of Internal Medicine; Том 12, № 5 (2022); 380-388 ; Архивъ внутренней медицины; Том 12, № 5 (2022); 380-388 ; 2411-6564 ; 2226-6704
Θεματικοί όροι: атеросклероз сонных артерий, peripheral atherosclerosis, renal atherosclerosis, carotid atherosclerosis, периферический атеросклероз, атеросклероз почечных артерий
Περιγραφή αρχείου: application/pdf
Relation: https://www.medarhive.ru/jour/article/view/1510/1159; https://www.medarhive.ru/jour/article/view/1510/1168; Барбараш, О.Л, Семенов В.Ю., Самородская И.В. Коморбидная патология у пациентов ишемической болезнью при коронарном шунтировании: опыт двух кардиохирургических центров. Россий ский кардиологический журнал. 2017; 3(143):6-13. DOI:10.15829/1560-4071-2017-3-6-13; Агеев, Ф.Т. Овчинников А.Г. Сердечная недостаточность с промежуточной фракцией выброса левого желудочка: существует ли клиническая необходимость выделения ее в отдельную подгруппу? Кардиология. 2018.; 58(12 S):4-10. DOI:10.18087/cardio.2609; Бойцов, С.А., Демкина А.Е., Ощепкова Е.В. и др. Достижения и проблемы практической кардиологии в России на современном этапе. Кардиология. 2019; 59(3): 53-59. DOI:10.18087/cardio.2019.3.10242; Гаврюшина, С.В., Агеев Ф.Т. Сердечная недостаточность с сохраненной фракцией выброса левого желудочка: эпидемиология, «портрет» пациента, клиника, диагностика. Кардиология. 2018; 58 (S4): 55-64. DOI:10.18087/cardio.2467; Kobzeva ND, Terentev VP., Zolotuhina I.Ways to optimize the prediction of vascular events in patients with acute coronary syndrome and atherosclerotic lesions of the renal arteries. IOP Conference Series Materials Science and Engineering. 2019; 680(1): 012046. 333-340. DOI:10.1088/1757-899X/680/1/012046; Aboyans V, Ricco JB, Bartelink MEL et al. ESC Scientific Document Group. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018; 39(9): 763-816. DOI:10.1093/eurheartj/ehx095; Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013; 34(28): 2159-219. DOI:10.1093/eurheartj/eht151; Мареев В.Ю., Фомин И.В., Агеев Ф.Т., и др. Клинические рекомендации. Хроническая сердечная недостаточность (ХСН). Журнал Сердечная Недостаточность. 2017; 18(1): 3–40. doi: DOI:10.18087/cardio.2475; Alagoz AN, Acar BA, Acar T, et al. Relationship Between Carotid Stenosis and Infarct Volume in Ischemic Stroke Patients. Med Sci Monit. 201616(22):4954-4959. DOI:10.12659/msm.898112.; Knappich C, Kuehn l A, Haller B, et al. Associations of Perioperative Variables With the 30-Day Risk of Stroke or Death in Carotid Endarterectomy for Symptomatic Carotid Stenosis. Stroke. 2019. 50(12): 439-3448. DOI:10.1161/STROKEAHA.119.026320.; Кобзева Н.Д. Особенности влияния атеросклеротического поражения различных сосудистых бассейнов на риск развития фатальных и нефатальных событий в отдаленном периоде. Терапия. 2021; 8: 70–75. doi: DOI:10.18565/therapy.2021.8.70-75; Ameri P., Schiattarella G., Crotti L., et al. Novel Basic Science Insights to Improve the Management of Heart Failure: Review of the WorkingGroup on Cellular and Molecular Biology of the Heart of the Italian Society of Cardiology .International journal of molecular sciences. 2020. 1192:1 — 17. DOI:10.3390/ijms21041192.; van Bilsen M, Patel HC, Bauersachs J, et al. The autonomic nervous system as a therapeutic target in heart failure: a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2017;19(11):1361-1378. DOI:10.1002/ejhf.921; Redfield MM. Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2016. 375(19): 1868-1877. DOI:10.1056/NEJMcp1511175; Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2017; 591-602. DOI:10.1038/nrcardio.2017.65; Hubesch G, Hanthazi A, Acheampong A et al. Preclinical Rat Model of Heart Failure With Preserved Ejection Fraction With Multiple Comorbidities. Front Cardiovasc Med. 2022; 8: 809885.1-15. DOI:10.3389/fcvm.2021.809885; Alherbish A, Becher H, Alemayehu W, et al. Impact of contrast echocardiography on accurate discrimination of specific degree of left ventricular systolic dysfunction and comparison with cardiac magnetic resonance imaging. Echocardiography. 2018; 35(11): 1746-1754. DOI:10.1111/echo.14152; Nagueh S, Smiseth O, Appleton C, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016; 277-314. DOI:10.1016/j.echo.2016.01.011; Morris DA, Ma XX, Belyavskiy E, et al. Left ventricularlongitudinal systolic function analysed by 2D speckle-tracking echocardiography in heart failure with preserved ejection fraction: a meta-analysis. Open Heart. 2017; 1-12 DOI:10.1136/openhrt-2017-000630; M, Patrono C, Collet J-P, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2016;37(3).267-315. DOI:10.1093/eurheartj/ehv320; Becker MAJ, Cornel JH, van de Ven PM, et al. The Prognostic Value of Late Gadolinium-Enhanced Cardiac Magnetic Resonance Imaging in Nonischemic Dilated Cardiomyopathy: A Review and Meta-Analysis. JACC Cardiovasc Imaging. 2018;11(9):1274-1284. DOI:10.1016/j.jcmg.2018.03.006; Zhao Y, Evans MA, Allison MA, et al. Multisite atherosclerosis in subjects with metabolic syndrome and diabetes and relation to cardiovascular events: The Multi-Ethnic Study of Atherosclerosis. Atherosclerosis. 2019; 282: 202-209. DOI:10.1016/j.atherosclerosis.2018.12.005; https://www.medarhive.ru/jour/article/view/1510
-
2Academic Journal
Συγγραφείς: I. Daabul S., A. Sokolova A., D. Napalkov A., И. Даабуль С., А. Соколова А., Д. Напалков А.
Πηγή: Rational Pharmacotherapy in Cardiology; Vol 12, No 5 (2016); 595-602 ; Рациональная Фармакотерапия в Кардиологии; Vol 12, No 5 (2016); 595-602 ; 2225-3653 ; 1819-6446 ; 10.20996/1819-6446-2016-12-5
Θεματικοί όροι: nonvalvular atrial fibrillation, chronic kidney disease, warfarin, direct oral anticoagulants, dabigatran, rivaroxaban, apixaban, renal arteries atherosclerosis, фибрилляция предсердий неклапанной этиологии, хроническая болезнь почек, варфарин, прямые пероральные антикоагулянты, дабигатран, ривароксабан, апиксабан, атеросклероз почечных артерий
Περιγραφή αρχείου: application/pdf
Relation: https://www.rpcardio.com/jour/article/view/1342/1385; Zoni-Berisso M., Lercari F., Carazza T., et al. Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol 2014; 6: 213-20.; National guidelines on the diagnosis and treatment of atrial fibrillation (2012). Available at: http://www.scardio.ru/content/Guidelines/FP_rkj_13.pdf. Retrieved 09/18/2016. In Russian (Национальные рекомендации по диагностике и лечению фибрилляции предсердий (2012). Доступно на: http://www.scardio.ru/content/Guidelines/FP_rkj_13.pdf.Проверено 18.09.2016).; Smirnov AV, Shilov EM, Dobronravov VA National guidelines. Chronic kidney disease: the basic principles of screening, diagnosis, prevention and treatment approaches. St. Petersburg: Levsha; 2012. In Russian (Смирнов А. В., Шилов Е. М., Добронравов В. А. Национальные рекомендации. Хроническая болезнь почек: основные принципы скрининга, диагностики, профилактики и подходы к лечению. СПб.: Левша: 2012).; Schwartzenberg, S., Lev EI., Sagie A., et al. The Quandary of Oral Anticoagulation in Patients With Atrial Fibrillation and Chronic Kidney Disease. Am J Cardiol 2016; 117(3): 477- 82.; Alonso A., Lopez FL., Matsushita K., et al. Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2011; 123(25): 2946-53.; Wheeler D.S., Giugliano R.P., Rangaswami J. Anticoagulation-related nephropathy. Thromb Haemost 2016; 14(3): 461-67.; Sardar P. Chatterjee S., Herzog E., et al. Novel oral anticoagulants in patients with renal insufficiency: a meta-analysis of randomized trials. Can J Cardiol 2014; 30(8): 888-97.; Schurgers L.J., Aebert H., Vermeer C., et al. Oral anticoagulant treatment: friend or foe in cardiovascular disease? Blood 2004; 104(10): 3231-2.; Pankratov V., Pigarova EA, Dzeranova L. K. Vitamin K-dependent proteins: osteocalcin, the Gla-protein matrix and vnekostnye effects. Ozhirenie i Metabolizm 2013; (2): 11-8. In Russian (Панкратова Ю. В., Пигарова Е. А., Дзеранова Л. К. Витамин К-зависимые белки: остеокальцин, матриксный Gla-белок и их внекостные эффекты. Ожирение и метаболизм 2013; (2): 11 - 8).; Luo G., Ducy P., McKee MD., et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997; 386(6620): 78-81.; Price P.A., Faus S.A., Williamson M.K. Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves. Arterioscler Thromb Vasc Biol 1998; 18(9): 1400-7.; Koos R., Mahnken AH., Mühlenbruch G., et al. Relation of oral anticoagulation to cardiac valvular and coronary calcium assessed by multislice spiral computed tomography. Am J Cardiol 2005; 96(6): 747-9.; Weijs B., Blaauw Y., Rennenberg RJ., et al. Patients using vitamin K antagonists show increased levels of coronary calcification: an observational study in low-risk atrial fibrillation patients. Eur Heart J 2011; 32(20): 2555-62.; Chatrou M.L., Winckers K., Hackeng TM., et al. Vascular calcification: the price to pay for anticoagulation therapy with vitamin K-antagonists. Blood Rev 2012; 26(4): 155-66.; Braam L.A., Hoeks AP., Brouns F., et al. Beneficial effects of vitamins D and K on the elastic properties of the vessel wall in postmenopausal women: a follow-up study. Thromb Haemost 2004; 91(2): 373-80.; Connolly S.J., Ezekowitz MD., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361(12): 1139-51.; Patel M.R., Mahaffey KW., Garg J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365(10): 883-91.; Granger C.B., Alexander JH., McMurray JJ., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365(11): 981-92.; Heidbuchel H., Verhamme P., Alings M., et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015; 17(10): 1467-507.; Hijazi Z., Hohnloser SH., Oldgren J., et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation 2014; 129(9): 961-70.; Böhm M., Ezekowitz MD., Connolly SJ., et al. Changes in Renal Function in Patients With Atrial Fibrillation: An Analysis From the RE-LY Trial. J Am Coll Cardiol 2015; 65(23): 2481-93.; Sparkenbaugh E.M., Chantrathammachart P., Mickelson J., et al. Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease. Blood 2014; 123(11): 1747-56.; Lee I.O., Kratz MT., Schirmer SH., et al. The effects of direct thrombin inhibition with dabigatran on plaque formation and endothelial function in apolipoprotein E-deficient mice. J Pharmacol Exp Ther 2012; 343(2): 253-7.; Preusch M.R., Ieronimakis N., Wijelath ES., et al. Dabigatran etexilate retards the initiation and progression of atherosclerotic lesions and inhibits the expression of oncostatin M in apolipoprotein E-deficient mice. Drug Des Devel Ther 2015; 9: 5203-11.; Hara T., Fukuda D., Tanaka K., et al. Rivaroxaban, a novel oral anticoagulant, attenuates atherosclerotic plaque progression and destabilization in ApoE-deficient mice. Atherosclerosis 2015; 242(2): 639-46.; Landray M.J., Wheeler DC., Lip GY., et al. Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study. Am J Kidney Dis 2004; 43(2): 244-53.; Brodsky S.V., Nadasdy T., Rovin BH., et al. Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate. Kidney Int 2011; 80(2): 181-9.; Brodsky S.V., Collins M., Park E., et al. Warfarin therapy that results in an International Normalization Ratio above the therapeutic range is associated with accelerated progression of chronic kidney disease. Nephron Clin Pract 2010; 115(2): 142-6.; Fox K.A., Piccini JP., Wojdyla D., et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J, 2011; 32(19): 2387-94.; Eto M., Barandiér C., Rathgeb L., et al. Thrombin suppresses endothelial nitric oxide synthase and upregulates endothelin-converting enzyme-1 expression by distinct pathways: role of Rho/ROCK and mitogen-activated protein kinase. Circ Res 2001; 89(7): 583-90.; Zhou, Q., Bea F., Preuschet M., al. Evaluation of plaque stability of advanced atherosclerotic lesions in apo E-deficient mice after treatment with the oral factor Xa inhibitor rivaroxaban. Mediators Inflamm 2011; 2011: 432080.; Mega J.L., Braunwald E., Wiviott SD., et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366(1): 9-19.; Hohnloser S.H., Hijazi Z., Thomas L., et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 2012; 33(22): 2821-30.; Esmon C.T. Targeting factor Xa and thrombin: impact on coagulation and beyond. Thromb Haemost 2014; 111(4): 625-33.; https://www.rpcardio.com/jour/article/view/1342